Business
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systemsTORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that its TULSA-PRO® system installed base stood at 78 as of December 31, 2025 — higher than
About this update from Profound Medical Corp
[{"type":"image","alt":"Profound Medical Corp.","displaySize":"","headline":null,"caption":"Profound Medical Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/706e95b61981393723638191940b98c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oleh9hsLn64FmkZjOMsmoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/706e95b61981393723638191940b98c5","width":300,"height":39}},"lazy":false},{"type":"text","content":"Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems","length":112,"tagName":"p"},{"type":"text","content":"TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that its TULSA-PRO® system installed base stood at 78 as of December 31, 2025 — higher than its previously announced goal of 75 installs by the end of 2025.","length":452,"tagName":"p"},{"type":"text","content":"Profound’s TULSA-PRO qualified sales pipeline also grew to 97 new systems being classified within one of the “Verify, Negotiate and Contracting” stages at year-end.","length":164,"tagName":"p"},{"type":"text","content":"“As the installed base grows, we expect that it will lead to higher patient treatment rates and, correspondingly, continued growth of our high margin recurring revenue,” said Profound’s CEO and Chairman, Arun Menawat. “That is being driven primarily by the TULSA Procedure’s ability to treat an unrivaled range of prostate diseases, severities, and aggressions, while preserving crucial functions like continence and sexual health of the patient. We look forward to releasing our fourth quarter and full year 2025 financial results near the end of February 2026.”","length":563,"tagName":"p"},{"type":"text","content":"About Profound Medical Corp.","length":28,"tagName":"p"},{"type":"text","content":"Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.","length":164,"tagName":"p"},{"type":"text","content":"Profound is commer...